Literature DB >> 19919837

Induction of p53 renders ATM-deficient mice refractory to hepatocarcinogenesis.

Narci Teoh1, Pawan Pyakurel, Yock Young Dan, Karen Swisshelm, Jing Hou, Claudia Mitchell, Nelson Fausto, Yansong Gu, Geoffrey Farrell.   

Abstract

BACKGROUND & AIMS: p53 Mutations are very common in human hepatocellular carcinoma, and induction of hepatic p53 expression causes lysis of implanted hepatoblastoma cells in a chimeric mouse. Ataxia Telangiectasia Mutated (ATM) kinase senses DNA strand breaks and induces p53. Our aims were to establish whether ATM deficiency alters the carcinogenic response of hepatocytes to diethylnitrosamine (DEN).
METHODS: Male ATM-deficient (ATM(-/-)), heterozygote (ATM(+/-)), and wild-type (WT) mice were injected with DEN at age 15 days, and animals were killed up to 12 months to assess p53, cell cycle, apoptosis, and liver tumor development.
RESULTS: Whereas >80% of WT and ATM(+/-) mice developed hepatocellular carcinoma (HCC), at 9-12 months, ATM(-/-) mice remained refractory to DEN-induced HCC up to 15 months. At 6 and 9 months, and compared with WT mice, p53 and p19(ARF) expression were greatly enhanced in ATM(-/-) liver associated with up-regulation of ATR and Chk1; cleaved caspase-3 immunohistochemistry and caspase-3 activity were also significantly increased. Whereas livers of DEN-treated ATM(-/-) mice showed markers of senescence (beta-galactosidase, Cxcl-1), up-regulation of telomerase occurred concurrently. The possibility that such balanced senescence could result in immortalization was demonstrated in hepatocytes prepared at 9 months from DEN-treated ATM(-/-) liver.
CONCLUSIONS: Hepatocarcinogenesis is abrogated in ATM-deficient mice in association with induction of ATR, Chk1, p53, and p19(ARF). Resultant cell cycle arrest and apoptosis of DNA-damaged cells are possible mechanisms that underlie this unique "refractoriness" to malignant transformation in DEN-initiated ATM(-/-) hepatocytes. The findings also show that prolonged up-regulation of p53 associated with some features of senescence does not inevitably cause organ failure. Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19919837     DOI: 10.1053/j.gastro.2009.11.008

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  13 in total

1.  Prognostic significance of ATM and cyclin B1 in pancreatic neuroendocrine tumor.

Authors:  Jae Uk Shin; Chang Hoon Lee; Kyu Taek Lee; Jong Kyun Lee; Kwang Hyuck Lee; Kwang Min Kim; Kyoung-Mee Kim; Sang-Mo Park; Jong Chul Rhee
Journal:  Tumour Biol       Date:  2012-06-16

Review 2.  Intracellular signaling and hepatocellular carcinoma.

Authors:  Polina Iakova; Lubov Timchenko; Nikolai A Timchenko
Journal:  Semin Cancer Biol       Date:  2010-09-17       Impact factor: 15.707

3.  Overexpression of CDT1 Is a Predictor of Poor Survival in Patients with Hepatocellular Carcinoma.

Authors:  Dimitrios Karavias; Ioannis Maroulis; Helen Papadaki; Charalambos Gogos; Stavros Kakkos; Dionissios Karavias; Vasiliki Bravou
Journal:  J Gastrointest Surg       Date:  2015-09-25       Impact factor: 3.452

4.  Astrocyte Elevated Gene-1 Regulates Macrophage Activation in Hepatocellular Carcinogenesis.

Authors:  Chadia L Robertson; Rachel G Mendoza; Nidhi Jariwala; Mikhail Dozmorov; Nitai D Mukhopadhyay; Mark A Subler; Jolene J Windle; Zhao Lai; Paul B Fisher; Shobha Ghosh; Devanand Sarkar
Journal:  Cancer Res       Date:  2018-09-04       Impact factor: 12.701

5.  Caspase-2 deficiency accelerates chemically induced liver cancer in mice.

Authors:  S Shalini; A Nikolic; C H Wilson; J Puccini; N Sladojevic; J Finnie; L Dorstyn; S Kumar
Journal:  Cell Death Differ       Date:  2016-08-12       Impact factor: 15.828

6.  TGFβ inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence.

Authors:  Thomas G Bird; Miryam Müller; Luke Boulter; David F Vincent; Rachel A Ridgway; Elena Lopez-Guadamillas; Wei-Yu Lu; Thomas Jamieson; Olivier Govaere; Andrew D Campbell; Sofía Ferreira-Gonzalez; Alicia M Cole; Trevor Hay; Kenneth J Simpson; William Clark; Ann Hedley; Mairi Clarke; Pauline Gentaz; Colin Nixon; Steven Bryce; Christos Kiourtis; Joep Sprangers; Robert J B Nibbs; Nico Van Rooijen; Laurent Bartholin; Steven R McGreal; Udayan Apte; Simon T Barry; John P Iredale; Alan R Clarke; Manuel Serrano; Tania A Roskams; Owen J Sansom; Stuart J Forbes
Journal:  Sci Transl Med       Date:  2018-08-15       Impact factor: 17.956

7.  The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation.

Authors:  C-C Chen; K-H Kim; L F Lau
Journal:  Oncogene       Date:  2015-06-01       Impact factor: 9.867

8.  Preemptive Homology-Directed DNA Repair Fosters Complex Genomic Rearrangements in Hepatocellular Carcinoma.

Authors:  Shirley Ming-Hui Sy; Yingying Guo; Ying Lan; Howin Ng; Michael Shing-Yan Huen
Journal:  Transl Oncol       Date:  2020-05-22       Impact factor: 4.243

9.  A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.

Authors:  Venturina Stagni; Simonetta Santini; Daniela Barilà
Journal:  Cancers (Basel)       Date:  2012-04-05       Impact factor: 6.639

10.  The Rad50 hook domain regulates DNA damage signaling and tumorigenesis.

Authors:  Ramon Roset; Akiko Inagaki; Marcel Hohl; Fabienne Brenet; Julien Lafrance-Vanasse; Julian Lange; Joseph M Scandura; John A Tainer; Scott Keeney; John H J Petrini
Journal:  Genes Dev       Date:  2014-02-14       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.